KN069 / Alphamab, Xiamen Amoytop Biotech - LARVOL DELTA

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. (PubMed, Diabetes Obes Metab) - P1 | "KN069 exhibits favourable safety, long-acting PK and preliminary dose-dependent weight reduction alongside expected pharmacologic metabolic effects, supporting further clinical development."

First-in-human • Journal • P1 data • PK/PD data • Genetic Disorders • Obesity

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Jun 2025 ➔ Jun 2027 | Trial primary completion date: Apr 2025 ➔ Apr 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity